부산대학교 도서관

A significant barrier to advancing the standard of care for patients with hematologic malignancies undergoing stem cell transplantation is access and willingness to participate in clinical trials. The importance of clinical trial enrollment is magnified in an era of targeted therapies, accelerated drug discovery, and investment by the pharmaceutical industry. As disease targets are identified, novel therapies are being evaluated in efforts to reduce treatment-related toxicity and improve progression-free and overall survival. The enrollment of hematopoietic cell transplantation ( HCT) patients on clinical studies is essential to promote the development of such therapies. Increasing clinical trial participation requires understanding of potential barriers to enrollment, including patient concerns, institutional and provider hurdles, and disease-specific characteristics. [ABSTRACT FROM AUTHOR]